Evan S Drake, Adriane B Marino, Jenna D Theroux, Kaitlin Roberts
{"title":"GLP-1 RAs: The newest powerhouse in metabolic medicine.","authors":"Evan S Drake, Adriane B Marino, Jenna D Theroux, Kaitlin Roberts","doi":"10.1097/01.NPR.0000000000000216","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>In the last decade, the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) drug class has revolutionized treatment for type 2 diabetes mellitus and some of its comorbidities, including obesity and cardiovascular disease. Continued advancements in the GLP-1 RA space show clinical promise for patients, though challenges-including barriers to care such as drug expense and availability-exist. This article provides an overview of available GLP-1 RAs and their mechanisms of action, indications, adverse reactions, and risks, providing practical pearls for providers along the way.</p>","PeriodicalId":51812,"journal":{"name":"NURSE PRACTITIONER","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NURSE PRACTITIONER","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.NPR.0000000000000216","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/25 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract: In the last decade, the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) drug class has revolutionized treatment for type 2 diabetes mellitus and some of its comorbidities, including obesity and cardiovascular disease. Continued advancements in the GLP-1 RA space show clinical promise for patients, though challenges-including barriers to care such as drug expense and availability-exist. This article provides an overview of available GLP-1 RAs and their mechanisms of action, indications, adverse reactions, and risks, providing practical pearls for providers along the way.
摘要：在过去十年中，胰高血糖素样肽-1（GLP-1）受体激动剂（RA）类药物彻底改变了 2 型糖尿病及其一些合并症（包括肥胖症和心血管疾病）的治疗方法。GLP-1 RA 领域的不断进步为患者带来了临床希望，但同时也存在着挑战，包括药物费用和可用性等治疗障碍。本文概述了现有的 GLP-1 RA 及其作用机制、适应症、不良反应和风险，并为医疗服务提供者提供了实用的指南。
期刊介绍：
With a circulation of 20,000, The Nurse Practitioner is the leading monthly source for clinical, practical, cutting-edge information for advanced practice nurses and other primary care clinicians. Each issue presents peer-reviewed articles that range from clinical topics and research to political and practice issues. In addition, The Nurse Practitioner provides regular features, columns, continuing education, staff development education, and more.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
